title: [Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes].
abstract: Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
authors.affiliation: Steno Diabetes Center, Universitets Hospitalet, Zürich, Universitet i Lund, og Karolinska Institutet, Stockholm. cmla@steno.dk
authors.forename: Claus Morten
authors.initials: CM
authors.lastname: Larsen
authors.forename: Mirjam
authors.initials: M
authors.lastname: Faulenbach
authors.forename: Allan
authors.initials: A
authors.lastname: Vaag
authors.forename: Aage
authors.initials: A
authors.lastname: Vølund
authors.forename: Jan
authors.initials: J
authors.lastname: Ehses
authors.forename: Burkhardt
authors.initials: B
authors.lastname: Seifert
authors.forename: Thomas
authors.initials: T
authors.lastname: Mandrup-Poulsen
authors.forename: Marc
authors.initials: M
authors.lastname: Donath